Granted Patent
B2
US 12,291,560 · App. 17/312,116 · Granted May 6, 2025
Dimerizing agent regulated immunoreceptor complexes
Assignee:
Regeneron Pharmaceuticals, Inc.
C07K14/70517A61K39/4611A61K39/4631A61K39/464411A61P35/02C07K14/70514C07K14/70578C12N15/86A61K38/00C07K2317/622C07K2319/03C07K2319/20C07K2319/33C07K2319/70C07K2319/92
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure provides improved compositions for adoptive T cell therapies targeting CD33 for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith. The present disclosure also relates to adoptive T cell therapies targeting CD33 and another target antigen for treating, preventing, or ameliorating at least one symptom of a cancer, infectious disease, autoimmune disease, inflammatory disease, and immunodeficiency, or condition associated therewith.
Claims (14)
1. A non-natural cell comprising:
(a) a first polypeptide comprising i) an FKBP-rapamycin binding (FRB) multimerization domain polypeptide; ii) a cluster of differentiation (CD)8α transmembrane domain; iii) a CD137 co-stimulatory domain; and iv) a CD3 ζ primary signaling domain; and
(b) a second polypeptide comprising i) a binding domain that binds to CD33, wherein the binding domain that binds to CD33 is a single chain Fv protein (scFv) comprising the amino acid sequence of SEQ ID NO:2; ii) an FK506 binding protein (FKBP) multimerization domain polypeptide; and iii) a CD4 transmembrane domain;
wherein the FKBP multimerization domain polypeptide is FKBP12 and wherein the FRB multimerization domain polypeptide is FRB T2098L.
2. The non-natural cell of claim 1 , wherein a bridging factor promotes formation of a polypeptide complex on the non-natural cell surface, wherein the bridging factor associates with the first and second polypeptides between the multimerization domains of the first and second polypeptides, and wherein the bridging factor is selected from the group consisting of AP21967, sirolimus, everolimus, novolimus, pimecrolimus, ridaforolimus, tacrolimus, temsirolimus, umirolimus, and zotarolimus.
3. The non-natural cell of claim 1 , wherein the second polypeptide comprises a costimulatory domain.
4. The non-natural cell of claim 3 , wherein the costimulatory domain of the second polypeptide is selected from a costimulatory molecule selected from the group consisting of Toll-like receptor 1 (TLR1), TLR2, TLR3, TLR4, TLR5, TLR6, TLR7, TLR8, TLR9, TLR10, caspase recruitment domain family member 11 (CARD11), CD2, CD7, CD27, CD28, CD30, CD40, CD54 (ICAM), CD83, CD94, CD134 (OX40), CD137 (4-1BB), CD278 (ICOS), DNA polymerase III subunit gamma/tau (DNAX)-activation protein 10 (DAP10),
linker for activation of T-cells family member 1 (LAT), Src Homology 2 (SH2) domain-containing leukocyte protein of 76 kD (SLP76), T cell receptor associated transmembrane adaptor 1 (TRAT1), tumor necrosis factor receptor superfamily member 14 (TNFRS14), TNFRS18, TNRFS25, and zeta chain of T cell receptor associated protein kinase 70 (ZAP70).
5. The non-natural cell of claim 4 , wherein the costimulatory domain of the second polypeptide is OX40.
6. The non-natural cell of claim 1 , wherein the first polypeptide, the second polypeptide, or both comprise a signal peptide.
7. The non-natural cell of claim 1 , wherein the first polypeptide comprises a CD8α signal peptide.
8. The non-natural cell of claim 1 , wherein the second polypeptide comprises an Igκ signal peptide.
9. A composition comprising the non-natural cell of claim 1 .
10. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the non-natural cell of claim 1 .
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 22, 2024
From: 2SEVENTY BIO, INC.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 067184/0161 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 14, 2021
From: BLUEBIRD BIO, INC.
To: 2SEVENTY BIO, INC.
Reel/Frame 057683/0099 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 2, 2021
From: JARJOUR, JORDAN; LEUNG, WAI-HANG
To: BLUEBIRD BIO, INC.
Reel/Frame 056745/0557 →
Continuity (3)
Provisional Application
62835662
· Apr 18, 2019
Provisional Application
62779953
· Dec 14, 2018
References Cited (146)
US 4751180A
· Cousens et al.
· 1988
[cited by applicant]
US 4935233A
· Bell et al.
· 1990
[cited by applicant]
US 5871753A
· Crabtree et al.
· 1999
[cited by applicant]
US 5910573A
· Pluckthun et al.
· 1999
[cited by applicant]
US 6291158B1
· Winter et al.
· 2001
[cited by applicant]
US 6291161B1
· Lerner et al.
· 2001
[cited by applicant]
US 6423498B1
· Markland et al.
· 2002
[cited by applicant]
US 6649595B2
· Clackson et al.
· 2003
[cited by applicant]
US 6692736B2
· Yu et al.
· 2004
[cited by applicant]
US 6972193B1
· Crabtree et al.
· 2005
[cited by applicant]
US 9587020B2
· Wu et al.
· 2017
[cited by applicant]
US 20120100160A1
· Lucas et al.
· 2012
[cited by applicant]
US 20160017302A1
· Dotti et al.
· 2016
[cited by applicant]
US 20200071399A1
· Jarjour et al.
· 2020
[cited by applicant]
JP 2002503667A
· 2002
[cited by applicant]
JP 2002508971A
· 2002
[cited by applicant]
WO WO1991009058A1
· 1991
[cited by applicant]
WO WO1999036553A2
· 1999
[cited by applicant]
WO WO1999041258A1
· 1999
[cited by applicant]
WO WO2003057171A2
· 2003
[cited by applicant]
WO WO2004043344A2
· 2004
[cited by applicant]
WO WO2006072620A1
· 2006
[cited by applicant]
WO WO2006095164A1
· 2006
[cited by applicant]
WO WO2007098934A1
· 2007
[cited by applicant]
WO WO2012082841A2
· 2012
[cited by applicant]
WO WO2014127261A1
· 2014
[cited by applicant]
WO WO2015017214A1
· 2015
[cited by applicant]
WO WO2015150526A2
· 2015
[cited by applicant]
WO WO2015150771A1
· 2015
[cited by applicant]
WO WO2016014553A1
· 2016
[cited by applicant]
WO WO2016014576A1
· 2016
[cited by applicant]
WO WO2017180993A1
· 2017
[cited by applicant]
WO WO2017214333A1
· 2017
[cited by applicant]
Abate-Daga et al., CAR models: next-generation CAR modifications for enhanced T-cell function. Mol Ther Oncolytics. May 18, 2016;3:16014, 7 pages.
[cited by applicant]
Alder et al., Antibody responses of variable lymphocyte receptors in the lamprey. Nat Immunol. Mar. 2008;9(3):319-27.
[cited by applicant]
Banaszynski et al., Characterization of the FKBP⋅Rapamycin⋅FRB Ternary Complex. J Am Chem Soc. 2005;127(13):4715-4721.
[cited by applicant]
Baral et al., Experimental therapy of African trypanosomiasis with a nanobody-conjugated human trypanolytic factor. Nat Med. May 2006;12(5):580-4.
[cited by applicant]
Barthelemy et al., Comprehensive analysis of the factors contributing to the stability and solubility of autonomous human VH domains. J Biol Chem. Feb. 8, 2008;283(6):3639-3654.
[cited by applicant]
Bayle et al., Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity. Chem Biol. Jan. 2006;13(1):99-107.
[cited by applicant]
Beavil et al., Alpha-helical coiled-coil stalks in the low-affinity receptor for IgE (Fc epsilon RII/CD23) and related C-type lectins. Proc Natl Acad Sci U S A. Jan. 15, 1992;89(2):753-7.
[cited by applicant]
Belshaw et al., Controlling protein association and subcellular localization with a synthetic ligand that induces heterodimerization of proteins. Proc Natl Acad Sci U S A. May 14, 1996;93(10):4604-7.
[cited by applicant]
Beste et al., Small antibody-like proteins with prescribed ligand specificities derived from the lipocalin fold. Proc Natl Acad Sci U S A. Mar. 2, 1999;96(5):1898-903.
[cited by applicant]
Binz et al., Designing repeat proteins: well-expressed, soluble and stable proteins from combinatorial libraries of consensus ankyrin repeat proteins. J Mol Biol. Sep. 12, 2003;332(2):489-503.
[cited by applicant]
Binz et al., Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol. Oct. 2005;23(10):1257-68.
[cited by applicant]
Bird et al., Single-chain antigen-binding proteins. Science. Oct. 21, 1988;242(4877):423-6.
[cited by applicant]
Brentjens et al., CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. Mar. 20, 2013;5(177):177ra38.
[cited by applicant]
Brentjens et al., Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. Nov. 3, 2011;118(18):4817-28.
[cited by applicant]
Brown et al., A mammalian protein targeted by G1-arresting rapamycin-receptor complex. Nature. Jun. 30, 1994;369(6483):756-8.
[cited by applicant]
Capon et al., Designing CD4 immunoadhesins for AIDS therapy. Nature. Feb. 9, 1989;337(6207):525-31.
[cited by applicant]
Carpenito et al., Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci U S A. Mar. 3, 2009;106(9):3360-5.
[cited by applicant]
Challita et al., Multiple modifications in cis elements of the long terminal repeat of retroviral vectors lead to increased expression and decreased DNA methylation in embryonic carcinoma cells. J Virol. Feb. 1995;69(2)…
[cited by applicant]
Chaudhary et al., A rapid method of cloning functional variable-region antibody genes in
[cited by applicant]
Cooper et al., T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect. Blood. Feb. 15, 2003;101(4):1637-44.
[cited by applicant]
Cortez-Retamozo et al., Efficient cancer therapy with a nanobody-based conjugate. Cancer Res. Apr. 15, 2004;64(8):2853-7.
[cited by applicant]
Craik et al., Plant cyclotides: A unique family of cyclic and knotted proteins that defines the cyclic cystine knot structural motif. J Mol Biol. Dec. 17, 1999;294(5):1327-36.
[cited by applicant]
Curran et al., Chimeric antigen receptors for T cell immunotherapy: current understanding and future directions. J Gene Med. Jun. 2012;14(6):405-15.
[cited by applicant]
De Felipe et al., Targeting of proteins derived from self-processing polyproteins containing multiple signal sequences. Traffic. Aug. 2004;5(8):616-26.
[cited by applicant]
Desjarlais et al., Length-encoded multiplex binding site determination: application to zinc finger proteins. Proc Natl Acad Sci U S A. Nov. 8, 1994;91(23):11099-103.
[cited by applicant]
Desjarlais et al., Use of a zinc-finger consensus sequence framework and specificity rules to design specific DNA binding proteins. Proc Natl Acad Sci U S A. Mar. 15, 1993;90(6):2256-60.
[cited by applicant]
Donnelly et al., The ‘cleavage’ activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring ‘2A-like’ sequences. J Gen Virol. May 2001;82(Pt 5):1027-1041.
[cited by applicant]
Dotti et al., Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev. Jan. 2014;257(1):107-26.
[cited by applicant]
Duke et al., Sequence and structural elements that contribute to efficient encephalomyocarditis virus RNA translation. J Virol. Mar. 1992;66(3):1602-9.
[cited by applicant]
Duong et al., Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy. Jan. 2011;3(1):33-48.
[cited by applicant]
Fegan et al., Chemically controlled protein assembly: techniques and applications. Chem Rev. Jun. 9, 2010;110(6):3315-36.
[cited by applicant]
Ghahroudi et al., Selection and identification of single domain antibody fragments from camel heavy-chain antibodies. FEBS Lett. Sep. 15, 1997;414(3):521-6.
[cited by applicant]
Grunberg et al., Building blocks for protein interaction devices. Nucleic Acids Res. May 2010;38(8):2645-62.
[cited by applicant]
Grupp et al., Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. Apr. 18, 2013;368(16):1509-1518.
[cited by applicant]
Haas et al., The Moloney murine leukemia virus repressor binding site represses expression in murine and human hematopoietic stem cells. J Virol. Sep. 2003;77(17):9439-50.
[cited by applicant]
Hackel et al., Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. J Mol Biol. Sep. 19, 2008;381(5):1238-52.
[cited by applicant]
Hamers-Casterman et al., Naturally occurring antibodies devoid of light chains. Nature. Jun. 3, 1993;363(6428):446-8.
[cited by applicant]
Herrin et al., Structure and specificity of lamprey monoclonal antibodies. Proc Natl Acad Sci USA. Feb. 12, 2008;105(6):2040-5.
[cited by applicant]
Hoet et al., Generation of high-affinity human antibodies by combining donor-derived and synthetic complementarity-determining-region diversity. Nat Biotechnol. Mar. 2005;23(3):344-8.
[cited by applicant]
Hsu et al., Primary human T lymphocytes engineered with a codon-optimized IL-15 gene resist cytokine withdrawal-induced apoptosis and persist long-term in the absence of exogenous cytokine. J Immunol. Dec. 1, 2005;175(1…
[cited by applicant]
Hu et al., Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. Jul. 1, 1996;56(13):3055-61.
[cited by applicant]
Huang et al., Scorpion-toxin mimics of CD4 in complex with human immunodeficiency virus gp120 crystal structures, molecular mimicry, and neutralization breadth. Structure. May 2005;13(5):755-68.
[cited by applicant]
Huez et al., Two independent internal ribosome entry sites are involved in translation initiation of vascular endothelial growth factor mRNA. Mol Cell Biol. Nov. 1998;18(11):6178-90.
[cited by applicant]
Irion et al., Identification and targeting of the ROSA26 locus in human embryonic stem cells. Nat Biotechnol. Dec. 2007;25(12):1477-82.
[cited by applicant]
Jackson et al., Internal initiation of translation in eukaryotes: the picornavirus paradigm and beyond. RNA. Dec. 1995;1(10):985-1000.
[cited by applicant]
Jackson et al., The novel mechanism of initiation of picornavirus RNA translation. Trends Biochem Sci. Dec. 1990;15(12):477-83.
[cited by applicant]
Janeway et al., Immunobiology: The Immune System in Health and Disease, 4th Edition. Current Biology Publications. pp. 148, 149 and 172, (1999).
[cited by applicant]
Jespers et al., Aggregation-resistant domain antibodies selected on phage by heat denaturation. Nat Biotechnol. Sep. 2004;22(9):1161-5.
[cited by applicant]
June et al., T-cell therapy at the threshold. Nat Biotechnol. Jul. 10, 2012;30(7):611-4.
[cited by applicant]
Kalos et al., T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. Aug. 10, 2011;3(95):95ra73.
[cited by applicant]
Kay, Structure-function relationships in the FK506-binding protein (FKBP) family of peptidylprolyl cis-trans isomerases. Biochem J. Mar. 1, 1996;314(Pt 2)(Pt 2):361-85.
[cited by applicant]
Kim et al., Hybrid restriction enzymes: zinc finger fusions to Fok I cleavage domain. Proc Natl Acad Sci U S A. Feb. 6, 1996;93(3):1156-60.
[cited by applicant]
Klemm et al., Dimerization as a regulatory mechanism in signal transduction. Annu Rev Immunol. 1998;16:569-92.
[cited by applicant]
Kochenderfer et al., B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. Mar. 22, 2012;119(12):2709…
[cited by applicant]
Kochenderfer et al., Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. May 2013;10(5):267-76.
[cited by applicant]
Kowolik et al., D28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells. Cancer Res. Nov. 15, 2006;66(22):10995-…
[cited by applicant]
Lee et al., Design of a binding scaffold based on variable lymphocyte receptors of jawless vertebrates by module engineering. Proc Natl Acad Sci U S A. Feb. 28, 2012;109(9):3299-304.
[cited by applicant]
Leung et al., Small Molecule-Regulated Antigen Recognition System for Inducible T Cell Targeting of CAncer Cells. Mol Ther. 2016;24:S110, Abstract No. 277.
[cited by applicant]
Liu et al., Design of polydactyl zinc-finger proteins for unique addressing within complex genomes. Proc Natl Acad Sci U S A. May 27, 1997;94(11):5525-30.
[cited by applicant]
Main et al., Design of stable alpha-helical arrays from an idealized TPR motif. Structure. May 2003;11(5):497-508.
[cited by applicant]
Manzke et al., CD3X anti-nitrophenyl bispecific diabodies: universal immunotherapeutic tools for retargeting T cells to tumors. Int J Cancer. Aug. 27, 1999;82(5):700-8.
[cited by applicant]
Maratea et al., Deletion and fusion analysis of the phage phi X174 lysis gene E. Gene. 1985;40(1):39-46.
[cited by applicant]
Martin et al., Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol. Jan. 2003;21(1):71-6.
[cited by applicant]
Milone et al., Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. Aug. 2009;17(8):1453-64.
[cited by applicant]
Murphy et al., Genetic construction, expression, and melanoma-selective cytotoxicity of a diphtheria toxin-related alpha-melanocyte-stimulating hormone fusion protein. Proc Natl Acad Sci U S A. Nov. 1986;83(21):8258-62.
[cited by applicant]
Nguyen et al., Heavy-chain antibodies in Camelidae; a case of evolutionary innovation. Immunogenetics. Apr. 2002;54(1):39-47.
[cited by applicant]
Nguyen et al., The specific variable domain of camel heavy-chain antibodies is encoded in the germline. J Mol Biol. Jan. 23, 1998;275(3):413-8.
[cited by applicant]
Nord et al., A combinatorial library of an alpha-helical bacterial receptor domain. Protein Eng. Jun. 1995;8(6):601-8.
[cited by applicant]
Nord et al., Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain. Nat Biotechnol. Aug. 1997;15(8):772-7.
[cited by applicant]
Nord et al., Recombinant human factor VIII-specific affinity ligands selected from phage-displayed combinatorial libraries of protein A. Eur J Biochem. Aug. 2001;268(15):4269-77.
[cited by applicant]
Parker et al., Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. Protein Eng Des Sel. Sep. 2005;18(…
[cited by applicant]
Patel et al., Impact of chimeric immune receptor extracellular protein domains on T cell function. Gene Ther. Mar. 1999;6(3):412-9.
[cited by applicant]
Pomerantz et al., Analysis of homeodomain function by structure-based design of a transcription factor. Proc Natl Acad Sci U S A. Oct. 10, 1995;92(21):9752-6.
[cited by applicant]
Pomerantz et al., Structure-based design of transcription factors. Science. Jan. 6, 1995;267(5194):93-6.
[cited by applicant]
Pule et al., A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells. Mol Ther. Nov. 2005;12(5):933-41.
[cited by applicant]
Quintarelli et al., Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. Oct. 15, 2007;110(8):2793-802.
[cited by applicant]
Restifo et al., Adoptive immunotherapy for cancer: harnessing the T cell response. Nat Rev Immunol. Mar. 22, 2012;12(4):269-81.
[cited by applicant]
Richards et al., Engineered fibronectin type III domain with a RGDWXE sequence binds with enhanced affinity and specificity to human alphavbeta3 integrin. J Mol Biol. Mar. 7, 2003;326(5):1475-88.
[cited by applicant]
Roux et al., Structural analysis of the nurse shark (new) antigen receptor (NAR): molecular convergence of NAR and unusual mammalian immunoglobulins. Proc Natl Acad Sci U S A. Sep. 29, 1998;95(20):11804-9.
[cited by applicant]
Ryan et al., Virus-encoded proteinases of the picornavirus super-group. J Gen Virol. Apr. 1997;78 ( Pt 4):699-723.
[cited by applicant]
Sato et al., Genes encoding putative natural killer cell C-type lectin receptors in teleostean fishes. Proc Natl Acad Sci U S A. Jun. 24, 2003;100(13):7779-84.
[cited by applicant]
Schlessinger, Cell signaling by receptor tyrosine kinases. Cell. Oct. 13, 2000;103(2):211-25.
[cited by applicant]
Schonfeld et al., An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies. Proc Natl Acad Sci U S A. May 19, 2009;106(20):8198-203.
[cited by applicant]
Skerra, Alternative binding proteins: anticalins—harnessing the structural plasticity of the lipocalin ligand pocket to engineer novel binding activities. FEBS J. Jun. 2008;275(11):2677-83.
[cited by applicant]
Spencer et al., Controlling signal transduction with synthetic ligands. Science. Nov. 12, 1993;262(5136):1019-24.
[cited by applicant]
Standaert et al., Molecular cloning and overexpression of the human FK506-binding protein FKBP. Nature. Aug. 16, 1990;346(6285):671-4.
[cited by applicant]
Stephan et al., T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection. Nat Med. Dec. 2007;13(12):1440-9.
[cited by applicant]
Stumpp et al., Designing repeat proteins: modular leucine-rich repeat protein libraries based on the mammalian ribonuclease inhibitor family. J Mol Biol. Sep. 12, 2003;332(2):471-87.
[cited by applicant]
Szymczak et al., Correction of multi-gene deficiency in vivo using a single ‘self-cleaving’ 2A peptide-based retroviral vector. Nat Biotechnol. May 2004;22(5):589-94.
[cited by applicant]
Tal et al., An NCR1-based chimeric receptor endows T-cells with multiple anti-tumor specificities. Oncotarget. Nov. 15, 2014;5(21):10949-58.
[cited by applicant]
Till et al., CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood. Apr. 26, 2012;119(17):3940-50.
[cited by applicant]
Varadamsetty et al., Designed Armadillo repeat proteins: library generation, characterization and selection of peptide binders with high specificity. J Mol Biol. Nov. 23, 2012;424(1-2):68-87.
[cited by applicant]
Vincke et al., General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold. J Biol Chem. Jan. 30, 2009;284(5):3273-3284.
[cited by applicant]
Vita et al., Scorpion toxins as natural scaffolds for protein engineering. Proc Natl Acad Sci U S A. Jul. 3, 1995;92(14):6404-8.
[cited by applicant]
Weisel et al., A model for fibrinogen: domains and sequence. Science. Dec. 20, 1985;230(4732):1388-91.
[cited by applicant]
White et al., Comparison of the glycosyl-phosphatidylinositol cleavage/attachment site between mammalian cells and parasitic protozoa. J Cell Sci. Feb. 2000;113 ( Pt 4):721-7.
[cited by applicant]
Wilkie et al., Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. Oct. 2012;32(5):1059-70.
[cited by applicant]
Zelensky et al., The C-type lectin-like domain superfamily. Febs J. Dec. 2005;272(24):6179-217.
[cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2019/066241, dated May 5, 2020, 14 pages.
[cited by applicant]